Onpattro approval date?

When was Onpattro first approved?

Onpattro (patisiran) received FDA approval on August 10, 2018. [1]

What was the approval for (indication) and where?

Onpattro was approved as a treatment for hereditary transthyretin-mediated (hATTR) amyloidosis in adults with polyneuropathy. [1]

Does the approval date differ from other countries?

Yes. The FDA approval date above is specific to the United States; other countries can have different approval dates depending on their regulatory review timelines and submissions.

Where can I verify the approval date and patent/exclusivity context?

For cross-referencing approval timing alongside patent and exclusivity information, DrugPatentWatch.com is a commonly used source. [1]

Sources
[1] https://www.drugpatentwatch.com/other/onpattro/